Acumen posts updated corporate presentation with additional ACU193 biomarker data at J.P. Morgan Healthcare Conference

Acumen Pharmaceuticals, Inc.

Company posted updated corporate presentation on its website with additional biomarker data for ACU193.
Presentation used at J.P. Morgan Healthcare Conference on January 8, 2024.
No specific financial results or guidance changes disclosed.
ACU193 is an investigational drug for Alzheimer's disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.